Arunis Abode moves to reshape its capital structure

The board resolution for the USD 65 million fundraising does not disclose the specific use of proceeds, such as project development milestones or debt repayment obligations.

Evidence The corporate update dated July 22, 2026, authorizes the issuance of various securities—including shares, convertible bonds, debentures, and warrants—but limits its disclosure to the fundraising amount, instrument types, and issuance methods ^[1]. The resolution grants the Board discretion to determine terms and conditions, including interest rates and discounts, but does not detail the intended application of the capital ^[1].

Implication Without a stated use of proceeds, the strategic intent behind this capital raise remains unconfirmed. Investors should monitor subsequent regulatory filings or investor presentations for clarity on whether these funds are earmarked for deleveraging, working capital, or specific growth projects.

The proposed capital infusion of up to USD 65 million approved by the Board of Kalind Limited (formerly Arunis Abode) ^[1] is highly transformational and entirely disproportionate to the company's current balance sheet scale.

Baseline Balance Sheet Position

As of the latest reported balance sheet period (Q3 FY25), Kalind Limited operates on a micro-scale capital base with minimal leverage:

• Notes: † Net Worth is derived from Total Debt of Rs 0.80 Crores ^[2] divided by the Gross Debt to Equity ratio of 0.13 x ^[6].*

Comparison of USD 65 Million Infusion

To compare the proposed capital raise with the company's baseline financials, the USD 65 million limit ^[1] is converted to Indian Rupees (Rs) using an illustrative exchange rate of Rs 83.5 per USD:

• INR Equivalent of Infusion: Approximately Rs 542.75 Crores (derived).
• Comparison to Net Worth: The proposed infusion of Rs 542.75 Crores is 88.25 times (or 8,825%) the company's current net worth of Rs 6.15 Crores (derived).
• Comparison to Existing Debt: The infusion is 678.44 times the existing total debt obligations of Rs 0.80 Crores ^[2].
• Comparison to Total Assets: The infusion represents 72.27 times the company's current total asset base of Rs 7.51 Crores ^[5].

Projected Impact on Debt-to-Equity Ratio

The board approval allows for a wide variety of fundraising instruments, including equity shares, convertible bonds, debentures, warrants, and Foreign Currency Convertible Bonds (FCCBs) ^[1]. Because the final mix of debt and equity instruments is not yet determined, the projected impact on the Gross Debt-to-Equity (D/E) ratio is highly binary:

• Notes: † Derived baseline. ‡ Derived assuming the full USD 65 million is raised at Rs 83.5 per USD (Rs 542.75 Crores).*
• Scenario A (Pure Equity / Warrants): If the entire USD 65 million is raised via equity shares or direct equity-linked instruments, the equity base expands to Rs 548.90 Crores. The projected D/E ratio falls from 0.13 x ^[6] to 0.00x (rounded), leaving the company virtually debt-free with massive cash reserves.
• Scenario B (Pure Debt / FCCBs Pre-Conversion): If the capital is raised entirely through debt instruments (such as unlisted debentures or FCCBs prior to any equity conversion), total debt would balloon to Rs 543.55 Crores. The projected D/E ratio would spike from 0.13 x ^[6] to 88.38x, representing an extremely high and unsustainable leverage profile for a company with only Rs 6.15 Crores in equity.

Strategic Implications

• Severe Dilution Risk: If the transaction is structured primarily through equity or convertible instruments, existing shareholders face extreme dilution. A capital infusion that is 88x the current net worth implies that existing shareholders will retain only a tiny fraction of the post-money equity.
• Deployment and Execution Risk: Expanding a balance sheet from Rs 7.51 Crores in assets ^[5] to over Rs 550 Crores overnight introduces unprecedented execution risk. The company's management will be challenged to productively deploy capital of this magnitude given its historically small operating footprint.
• Capital Structure Flexibility: The inclusion of FCCBs and convertible bonds in the board approval ^[1] suggests a desire to defer immediate equity dilution, though this carries the risk of temporary balance sheet over-leveraging (as shown in Scenario B) until conversion triggers are met.

Material Gaps and Uncertainties

• "Up to" Clause: The board approval is for an amount *not exceeding* USD 65 million ^[1]. The actual amount raised could be significantly lower, which would scale down the balance sheet impact proportionally.
• Instrument Mix: The exact ratio of equity, warrants, debentures, and FCCBs has not been finalized ^[1]. The actual post-money D/E ratio will sit somewhere between the 0.00x and 88.38x extremes calculated above.
• Exchange Rate Volatility: Because the approval is denominated in USD ^[1], the final rupee proceeds and corresponding balance sheet impact will fluctuate based on the prevailing USD/INR exchange rate at the time of pricing.

The board of Kalind Limited (formerly Arunis Abode) has approved a flexible fundraising framework for up to USD 65 million, but the specific dilution impact for existing shareholders remains indeterminate as the company has not yet finalized the pricing, conversion ratios, or the specific mix of instruments to be issued ^[1].

Proposed Issuance Structure

The board has authorized the issuance of a wide range of securities, providing the company with significant flexibility to tailor the capital raise to market conditions. The approved instruments include:

• Equity shares (issued for cash or other than cash)
• Convertible bonds and debentures
• Warrants
• Preference shares
• Foreign currency convertible bonds (FCCBs)
• Any other equity-linked securities ^[1]

These securities may be issued through various methods, including preferential issues, private placements, qualified institutional placements (QIPs), or share swaps, either in one or more tranches ^[1].

Dilution and Disclosure Gaps

The maximum potential dilution to existing shareholders cannot be determined from the current disclosures. The board has been granted the authority to determine the terms and conditions—including security, interest rates, and discounts—at its absolute discretion, subject to subsequent shareholder and regulatory approvals ^[1]. Consequently, the final equity impact will depend on the specific instrument chosen, the conversion price, and the prevailing market price at the time of issuance.